Etanercept News and Research

RSS
Etanercept (Enbrel) is a drug that treats autoimmune diseases by interfering with the TNF receptor (a part of the immune system) by acting as a TNF inhibitor.
FOI technique found to be effective in detecting joint inflammation in children

FOI technique found to be effective in detecting joint inflammation in children

Research findings provide insight into mechanisms underlying differences in efficacy of anti-TNF drugs

Research findings provide insight into mechanisms underlying differences in efficacy of anti-TNF drugs

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

New report reveals prescription medication costs may increase up to 13% in 2016

New report reveals prescription medication costs may increase up to 13% in 2016

New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

Factors other than just cost may influence prescribing of TNF inhibitors for RA patients

Factors other than just cost may influence prescribing of TNF inhibitors for RA patients

Antiinflammatory drug HUMIRA enhances specific TNF function in rheumatoid arthritis patients

Antiinflammatory drug HUMIRA enhances specific TNF function in rheumatoid arthritis patients

Lilly's ixekizumab (Taltz) granted EC marketing authorisation for treatment of plaque psoriasis

Lilly's ixekizumab (Taltz) granted EC marketing authorisation for treatment of plaque psoriasis

New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Lilly announces CHMP positive opinion for ixekizumab for treatment of adults with plaque psoriasis

Lilly announces CHMP positive opinion for ixekizumab for treatment of adults with plaque psoriasis

BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

New BSR guidelines on prescribing anti-rheumatic medication during pregnancy, breastfeeding

New BSR guidelines on prescribing anti-rheumatic medication during pregnancy, breastfeeding

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

Study: New test may help predict effectiveness of biologic drugs in RA patients

Study: New test may help predict effectiveness of biologic drugs in RA patients

Study shows that TNFi dose reduction strategy can help in optimal management of RA

Study shows that TNFi dose reduction strategy can help in optimal management of RA

Ixekizumab drug shows quick and extensive improvements in patients with psoriasis

Ixekizumab drug shows quick and extensive improvements in patients with psoriasis

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Australian Prescriber publishes top 10 subsidised drugs in Australia

Australian Prescriber publishes top 10 subsidised drugs in Australia